Skip to main content
SpringerLink
Log in

Marqueurs biochimiques du remodelage osseux: utilité pratique dans la gestion des métastases osseuses des cancers mammaires

  • Conference paper
Cancer du sein

  • 277 Accesses

Abstrait

La formation et la dégradation du tissu osseux peuvent être évaluées par la mesure d’une activité enzymatique des cellules osseuses (activité phosphatase acide ou phosphatase alcaline), ou en mesurant des produits de la matrice osseuse libérés lors de la formation ou de la résorption tels l’ostéocalcine ou les fragments du collagène de type I (11).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Ali SM, Demers LM, Leitzel K et al. (2004) Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15: 455–459

    Article  PubMed  CAS  Google Scholar 

  2. Body JJ, Dumon JC, Gineyts E et al. (1997) Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 75: 408–412

    PubMed  CAS  Google Scholar 

  3. Bombardieri E, Martinetti A, Miceli R et al. (1997) Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer? Eur J Nucl Med 24: 1349–1355

    Article  PubMed  CAS  Google Scholar 

  4. Brown JE, Cook RJ, Major P et al. (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97: 59–69

    Article  PubMed  CAS  Google Scholar 

  5. Coleman RE, Major P, Lipton A et al. (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925–4935

    Article  PubMed  CAS  Google Scholar 

  6. Coleman RE (2006) The role of bone markers in metastatic bone disease. Cancer Treat Rev 32Suppl 1: 1–2

    Article  PubMed  Google Scholar 

  7. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243s–6249s

    Article  PubMed  Google Scholar 

  8. Coleman RE (2006) Conclusion: Bone markers in metastatic bone disease. Cancer Treat Rev 32Suppl 1: 27–28

    Article  PubMed  Google Scholar 

  9. Costa L, Demers LM, Gouveia-Oliveira A et al. (2002) Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20: 850–856

    Article  PubMed  CAS  Google Scholar 

  10. Demers LM (2003) Bone markers in the management of patients with skeletal metastases. Cancer 97: 874–879

    Article  PubMed  Google Scholar 

  11. Demers LM, Costa L, Lipton A (2003) Biochemical markers and skeletal metastases. Clin Orthop Relat Res S138–147

    Google Scholar 

  12. Fohr B, Dunstan CR, Seibel MJ (2003) Clinical review 165: Markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 88: 5059–5075

    Article  PubMed  CAS  Google Scholar 

  13. Garnero P (2006) Marqueurs biochimiques du remodelage osseux et metastases osseuses Cours sur les métastases osseuses. Université d’été francophone. Chantilly

    Google Scholar 

  14. Garnero P, Delmas PD (1993) Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77: 1046–1053

    Article  PubMed  CAS  Google Scholar 

  15. Lipton A (2006) Biochemical bone markers in breast cancer. Cancer Treat Rev 32Suppl 1: 20–22

    Article  PubMed  CAS  Google Scholar 

  16. Palma MA, Body JJ (2005) Usefulness of bone formation markers in breast cancer. Int J Biol Markers 20: 146–155

    PubMed  CAS  Google Scholar 

  17. Rosen LS, Gordon D, Kaminski M et al. (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377–387

    PubMed  CAS  Google Scholar 

  18. Tahtela R, Tholix E (1996) Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res 16: 2289–2293

    PubMed  CAS  Google Scholar 

  19. Saad F (2006) Optimizing patient therapy: the role of bone markers? Cancer Treat Rev 32Suppl 1: 3–6

    Article  PubMed  Google Scholar 

  20. Seibel MJ, Koeller M, Van der Velden B, Diel I (2002) Markers of bone turnover do not predict bone metastases in breast cancer. Clin Lab 48: 583–588

    PubMed  CAS  Google Scholar 

  21. Vinholes J, Coleman R, Lacombe D et al. (1999) Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. Br J Cancer 80: 221–228

    Article  PubMed  CAS  Google Scholar 

  22. Vinholes J, Guo CY, Purohit OP et al. (1996) Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 73: 1089–1095

    PubMed  CAS  Google Scholar 

  23. Walls J, Assiri A, Howell A et al. (1999) Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases. Br J Cancer 80: 1265–1270

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Services d’oncologie médicale et de statistique, Centre René Huguenin, 35, rue Dailly, 92210, Saint-Cloud

    M. Tubiana-Hulin

Authors
  1. M. Tubiana-Hulin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France, Paris

About this paper

Cite this paper

Tubiana-Hulin, M. (2007). Marqueurs biochimiques du remodelage osseux: utilité pratique dans la gestion des métastases osseuses des cancers mammaires. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/978-2-287-71478-8_45

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-71478-8_45

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-71477-1

  • Online ISBN: 978-2-287-71478-8

Publish with us

Policies and ethics

Search

Navigation